The immunosuppressive agent FK506 enhances the cytolytic activity of inhibitory natural killer cell receptor (CD94/NKG2A)-expressing CD8 T cells

Transplantation

Volumn 80, Issue 12, 2005, Pages 1813-1815

  Tanaka, Junji ^a   Toubai, Tomomi ^a   Iwao, Noriaki ^a   Tsutsumi, Yutaka ^a   Kato, Naoko ^a   Miura, Yoko ^a   Shigematsu, Akio ^a   Hirate, Daisuke ^a   Ota, Shuichi ^a   Asaka, Masahiro ^a   Imamura, Masahiro ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CTL; FK506; GVL; Natural killer cell

Indexed keywords

CD8 ANTIGEN; CD94 ANTIGEN; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; GRANZYME A; HLA ANTIGEN CLASS 1; HLA E ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR NKG2A; RECEPTOR SUBUNIT; TACROLIMUS;

ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOPHARMACOLOGY; IN VITRO STUDY; INHIBITION KINETICS; LYMPHOCYTE CULTURE; LYMPHOCYTE FUNCTION; NATURAL KILLER T CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR DENSITY; TARGET CELL DESTRUCTION; TRANSCRIPTION REGULATION;

ANTIGENS, CD94; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-15; LYMPHOCYTE ACTIVATION; TACROLIMUS;

EID: 30144432160     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000188695.72228.e4     Document Type: Article

References (20)

1. Ljunggren HG, Karre K. In search of the "missing self". MHC molecules and NK cell recognition. Immunol Today 1990; 11: 237-244.
2. Moretta A, Biassoni R, Bottino C, et al. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol Rev 1997; 155: 105-117.
3. Bakker ABH, Phillips JH, Figdor CG, Lanier LL. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, γδ T cells, and antigen-specific CTL. J Immunol 1998; 160: 5239-5245.
4. Phillips JH, Gumperz JE, Parham P, Lanier LL. Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. Science 1995; 268: 403-405.
5. + T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc Natl Acad Sci USA 1996; 93: 12433-12438.
6. + T cells is controlled by T-cell receptor engagement. Nature 2000; 403: 325-328.
7. Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391: 795-799.
8. Borrego F, Ulbrech M, Weiss EH, et al. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLAS class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998; 187: 813-818.
9. Tanaka J, Toubai T, Tsutsumi Y, et al. Cytolytic activity and regulatory functions of inhibitory NK cell receptor-expressing T cells expanded from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 2004; 104: 768-774.
10. Tanaka J, Iwao N, Toubai T, et al. Cytolytic activity against primary leukemic cells by inhibitory NK cell receptor (CD94/NKG2A)-expressing T cells expanded from various sources of blood mononuclear cells. Leukemia 2005; 19: 486-489.
11. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002; 128: 255-266.
12. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136-142.
13. Nash RA, Pineiro LA, Storb R, et al. 506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996; 88: 3634-4361.
14. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-2068.
15. Wasik M, Gorski A, Stepien-Sopniewska B, Lagodzinski Z. Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. Transplantation 1991; 51: 268-270.
16. Alamartine E, Sabido O, Berthoux F. In-vitro effects of cyclosporin A, FK506,6-mercaptopurine, and prednisolone on lymphokine-activated killer cells. Nephrol Dial Transplant 1994; 9: 1456-1461.
17. Kataoka T, Nagai K. Involvement of FK506-sensitive and insensitive granule exocytosis pathways in perforin-dependent target cell lysis mediated by a CD8+ CTL clone. Immunol Lett 2000; 72: 49-52.
18. Maruyama M, Suzuki H, Yamashita N, Yano S. Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. Transplantation 1990; 50: 272-277.
19. Bishop DK, Li W. Cyclosporin A and FK506 mediate differential effects on T cell activation in vivo. J Immunol 1992; 148: 1049-1054.
20. Roelen DL, van Bree FP, Schanz U, et al. Differential inhibition of primed alloreactive CTLs in vitro by clinically used concentrations of cyclosporine and FK506. Transplantation 1993; 56: 190-195.